🧾 What This Document Is

This is a DEF 14A, also known as a Proxy Statement. It's a formal document sent to shareholders before an annual meeting. Its job is to give you all the information you need to vote on important company decisions.

👉 In simple terms: Think of it as a detailed agenda and voter's guide for Pacific Biosciences' big yearly meeting. You'll find out what's being voted on, who's running the company, and how much the top executives get paid.

🏢 What The Company Does

Pacific Biosciences (PacBio) creates advanced DNA sequencing systems. These are high-tech machines that help scientists "read" genetic code very accurately and at long lengths.

👉 Why it matters: Their technology is used in crucial research, like studying complex genomes (the complete set of DNA) and understanding diseases. They compete in the fast-growing genomics industry, which powers everything from personalized medicine to agricultural science.

🗳️ What You're Voting On: The Four Key Proposals

The annual meeting will be virtual on June 3, 2026. Shareholders owning stock as of April 6, 2026, get to vote on these four main items:

Proposal 1: Elect Six Directors. Vote for the people who will oversee the company's strategy and management.
Proposal 2: Ratify the Auditor. Approve Ernst & Young LLP as the independent accounting firm for 2026. This is a routine check on the company's financial books.
Proposal 3: Advisory Vote on Executive Pay ("Say-on-Pay"). A non-binding vote to approve the compensation package for the top executives.
Proposal 4: Expand the Employee Stock Plan. Approve an amendment to the 2020 Equity Incentive Plan to increase the number of shares reserved for granting to employees. This is crucial for attracting and retaining talent.

👉 The Board's Recommendation: They advise shareholders to vote "FOR" on all four proposals.

👥 Meet the Leadership: Director Nominees

The company is recommending nine directors (down from ten after the meeting). Here are the key figures:

Christian O. Henry: The President & CEO. He’s been in the top job since 2020 and has deep experience from his time at Illumina.
John F. Milligan, Ph.D.: The Chairman of the Board. Former CEO of Gilead Sciences, bringing major biotech executive experience.
New Nominee - Chris Gibson, Ph.D.: Co-founder of Recursion Pharmaceuticals. He brings expertise in using data and AI for drug discovery.
Other Nominees: Include experts from venture capital (William Ericson), diagnostics (Kathy Ordoñez, Christopher M. Smith), finance (Randy Livingston, Marshall Mohr), and medical science (Hannah A. Valantine, M.D.).

👉 Why it matters: This board combines deep industry knowledge, financial oversight, and commercial experience to guide a complex tech company.

💼 Executive Compensation: How Top Leaders Are Paid

The proxy details how much the named executive officers (NEOs) were paid in 2025. The main components are:

Salary: The fixed cash pay.
Bonus: Annual cash incentives for hitting goals.
Stock Awards: The biggest part of compensation, designed to tie executive success directly to shareholder returns over the long term.
Option Awards: Similar to stock awards, giving the right to buy shares at a set price.

👉 The big picture: Most of the CEO's pay ($1,041,346 salary) is "at-risk," meaning it comes from performance-based bonuses and long-term stock awards. This structure is meant to align his interests with yours as a shareholder.

🏛️ How the Company is Governed

PacBio outlines its governance framework, emphasizing oversight and ethics.

Board Structure: The CEO and Chairman roles are separated, which is often seen as a good governance practice for balance of power.
Key Committees:
- Audit Committee: Oversees financial reporting and internal controls. Chaired by Marshall Mohr.
- Compensation Committee: Sets executive pay. Chaired by Kathy Ordoñez.
- Governance & Nominating Committee: Finds director candidates and reviews governance. Chaired by William Ericson.
- Science & Technology Committee: Advises on R&D and innovation strategy. A unique committee reflecting the company's tech focus.
Risk Oversight: The Board, through its committees, actively oversees major risks, including cybersecurity and compensation practices.

🔮 What's Next & Strategic Focus

While the proxy is about governance, it points to the company's strategic direction:

Talent Investment: Proposing to expand the equity plan (Proposal 4) shows a focus on retaining the skilled workforce needed to compete.
Innovation: The dedicated Science & Technology Committee highlights that staying at the cutting edge of sequencing tech is a top board-level priority.
Commercial Execution: Bringing on new directors with commercial and operational expertise (like Christopher Smith) signals a drive to improve market penetration and revenue growth.

⚖️ Big Picture: Strengths & Risks

👍 Strengths: A strong, independent board with relevant expertise; a compensation plan tied to performance; a clear governance structure; and a strategic focus on innovation through its unique board committee.
⚠️ Risks: The company operates in a highly competitive, capital-intensive industry. Approval of the expanded equity plan dilutes existing shareholders, and the "Say-on-Pay" vote, while advisory, reflects shareholder sentiment on whether executive rewards are truly aligned with company performance.

🧠 The Analogy

Think of this proxy statement as a corporate "playbook" and annual report card. It’s the rulebook for the company's leadership election and a report on how the coaches (executives) were compensated last season. Your vote helps decide the playbook for the coming year.

🧩 Final Takeaway

This proxy statement is your toolkit for influencing Pacific Biosciences' future. The key decisions are electing a board with deep biotech and commercial experience and approving an expanded stock plan critical for keeping top talent in a competitive field. Your vote directly shapes the company's leadership and its ability to execute its scientific mission.

PACB Shareholders to Vote on Four Key Proposals Including Equity Plan Expansion